Table 3 Candidate stem cell-specific genes for each cancer type
Cancer Type(Percentage) | Genes(Percentage) |
|---|---|
ACC (56.5) | HDAC2 (5.4), ERCC2 (20.7), GARS (38.0), PRR34 (8.7) |
BLCA (30.3) | CHEK2 (6.1), ERCC2 (9.7),KMT2C (20.9) |
BRCA (8.2) | KMT2C (6.9), PILRB (0.8), HLA_DRB5 (0.7) |
CHOL (33.3) | CHEK2 (8.3),KMT2C (25),GIMAP8 (2.8) |
COAD (1.5) | HLA_DPA1 (1.5), |
ESCA (9.3) | NREP (2.2),BRINP1 (7.7) |
GBM (4.4) | CHEK2 (1.8),TSHZ2 (2.5) |
HNSC (20.4) | CHEK2 (3.8), LIN28B (1.5), BRINP1 (3.1), KMT2C (12.0), NPR3 (2.7) |
KICH.21.2) | DIMT1 (1.5),KMT2C (13.6),HLA_DRB5 (7.6), HLA_DQA1 (3) |
LIHC (5) | HTR7 (5) |
KIRC (11.1) | DNMT3B (3.1), CHEK2 (2.2), RRAS2 (1.8), NREP (0.7), TNFSF10 (1.3), FYB (2.9), SMARCC2 (3.1), RCSD1 (2), HLA_DRB5 (1.8) |
KIRP (7.1) | CHEK2 (5.9), DPH3(1.2) |
LGG (9.3) | CHEK2(3.9),HDAC2(1.7),ZBTB20(4.6) |
LUAD (42.0) | SPDL1 (1.8), CHEK2 (7.2), TRPC4 (7.2), CDH6 (7.2), GIMAP1 (2.2), KMT2C (17.8), PILRB (2.2), TSHZ2 (6.8), NPR3 (4.6), FYB (5.5) |
OV (2.6) | BOD1 (0.9), HAS2 (1.7) |
PAAD (57.3) | CHEK2 (17.0), BBS9 (9.4), GARS (5.8), SLC24A1 (9.4), KMT2C (17), SMARCC2 (13.5), NPR3 (8.8), AFTPH (13.5) |
PCPG (14.3) | CHEK2 (5.1), NUSAP1 (4.0), KMT2C (5.1), HLA_DRB5(1.1) |
PRAD (8.9) | CHEK2(3.5),KMT2C(5.4) |
SARC (4.3) | ZNF788 (2.8), BRINP1 (2.0) |
SKCM (37.3) | GDF3 (8.0), CCDC90B (4.0), CDH6 (10.7), KMT2C (16.0), GIMAP5 (6.7) ,GIMAP7 (6.7),GIMAP1 (6.7),GIMAP8 (12) |
STAD (32.3) | CHEK2 (5.4), SOHLH2 (4.4), BRINP1 (5.9), KMT2C (16.5), TSHZ2(7.2),ZBTB20(9) |
TGCT (2.8) | C10orf128 (2.1), HLA_DRB5 (2.1), HLA_DQA1 (1.4) |
THCA (4.8) | CHEK2 (1.4), GDF3 (0.8), RIOK2 (0.8), HLA_DRB5 (1.7) |
THYM (5.7) | CHEK2 (5.7) |
UCEC (9.7) | ATP11C (9.7) |
UCS(15.8) | CHEK2(7),KMT2C(10.) |
UVM(13.8) | CHEK2(7.5),NUSAP1(5),HLA_DRB5(5) |
Pan Cancer(24.3) | CHEK2 (4.1), SOHLH2 (1), BRINP1 (2.2), TRPC4 (2.4), CDH6 (2.1), KMT2C (10.6), PILRB (0.8) ,HLA_DRB5 (1.1), TSHZ2 (2.6), NPR3 (1.7),GIMAP1 (0.9), GIMAP8(1.7),ZBTB20(2.1) |